Download PDF
Semin Thromb Hemost 2010; 36(4): 367-377
DOI: 10.1055/s-0030-1254046
© Thieme Medical Publishers

Disseminated Intravascular Coagulation in Infectious Disease

Marcel Levi1 , Marcus Schultz2 , Tom van der Poll1 , 3 , 4
  • 1Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • 2Department of Intensive Care, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • 3Center for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
  • 4Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Further Information

Publication History

Publication Date:
07 July 2010 (online)

    Permissions and Reprints

ABSTRACT

Severe infection and inflammation almost invariably lead to hemostatic abnormalities, ranging from insignificant laboratory changes to severe disseminated intravascular coagulation. Systemic inflammation as a result of severe infection leads to activation of coagulation, due to tissue factor–mediated thrombin generation, downregulation of physiological anticoagulant mechanisms, and inhibition of fibrinolysis. Proinflammatory cytokines play a central role in the differential effects on the coagulation and fibrinolysis pathways. Vice versa, activation of the coagulation system may importantly affect inflammatory responses by direct and indirect mechanisms. Apart from the general coagulation response to inflammation associated with severe infection, specific infections may cause distinct features, such as hemorrhagic fever or thrombotic microangiopathy. The relevance of the cross-talk between inflammation and coagulation is underlined by the results of the treatment of severe systemic infection with modulators of coagulation and inflammation.

KEYWORDS

Disseminated intravascular coagulation - infection - inflammation - cytokines - tissue factor - antithrombin - protein C - fibrinolysis

REFERENCES

  • 1 Levi M. Disseminated intravascular coagulation.  Crit Care Med. 2007;  35(9) 2191-2195
    CrossrefPubMedGoogle Scholar
  • 2 Levi M, Ten Cate H. Disseminated intravascular coagulation.  N Engl J Med. 1999;  341(8) 586-592
    CrossrefPubMedGoogle Scholar
  • 3 Levi M, van der Poll T. Inflammation and coagulation.  Crit Care Med. 2010;  38(2, suppl) S26-S34
    CrossrefPubMedGoogle Scholar
  • 4 Aird W C. Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis.  Crit Care Med. 2001;  29(7, suppl) S28-S34, discussion S34–S35
    CrossrefPubMedGoogle Scholar
  • 5 Wheeler A P, Bernard G R. Treating patients with severe sepsis.  N Engl J Med. 1999;  340(3) 207-214
    CrossrefPubMedGoogle Scholar
  • 6 Levi M, de Jonge E, van der Poll T, ten Cate H. Disseminated intravascular coagulation.  Thromb Haemost. 1999;  82(2) 695-705
    PubMedGoogle Scholar
  • 7 Anas A, Wiersinga W J, de Vos A F, van der Poll T. Recent insights into the pathogenesis of bacterial sepsis.  Neth J Med. 2010;  68 147-152
    PubMedGoogle Scholar
  • 8 ten Cate J W, van der Poll T, Levi M, ten Cate H, van Deventer S J. Cytokines: triggers of clinical thrombotic disease.  Thromb Haemost. 1997;  78(1) 415-419
    PubMedGoogle Scholar
  • 9 Levi M, ten Cate H, van der Poll T. Endothelium: interface between coagulation and inflammation.  Crit Care Med. 2002;  30(5, suppl) S220-S224
    CrossrefPubMedGoogle Scholar
  • 10 Vallet B. Microthrombosis in sepsis.  Minerva Anesthesiol. 2001;  67(4) 298-301
    PubMedGoogle Scholar
  • 11 Levi M, van der Poll T, ten Cate H, van Deventer S J. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia.  Eur J Clin Invest. 1997;  27(1) 3-9
    CrossrefPubMedGoogle Scholar
  • 12 Ruf W, Edgington T S. Structural biology of tissue factor, the initiator of thrombogenesis in vivo.  FASEB J. 1994;  8(6) 385-390
    PubMedGoogle Scholar
  • 13 Camerer E, Kolstø A B, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation.  Thromb Res. 1996;  81(1) 1-41
    CrossrefPubMedGoogle Scholar
  • 14 Banner D W, D'Arcy A, Chène C et al.. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor.  , [see comments] Nature. 1996;  380(6569) 41-46
    CrossrefPubMedGoogle Scholar
  • 15 ten Cate H, Bauer K A, Levi M et al.. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.  J Clin Invest. 1993;  92(3) 1207-1212
    CrossrefPubMedGoogle Scholar
  • 16 Osterud B. Tissue factor expression by monocytes: regulation and pathophysiological roles.  Blood Coagul Fibrinolysis. 1998;  9(suppl 1) S9-S14
    PubMedGoogle Scholar
  • 17 Giesen P L, Rauch U, Bohrmann B et al.. Blood-borne tissue factor: another view of thrombosis.  Proc Natl Acad Sci U S A. 1999;  96(5) 2311-2315
    Google Scholar
  • 18 Nieuwland R, Berckmans R J, McGregor S et al.. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis.  Blood. 2000;  95(3) 930-935
    PubMedGoogle Scholar
  • 19 Koyama T, Nishida K, Ohdama S et al.. Determination of plasma tissue factor antigen and its clinical significance.  Br J Haematol. 1994;  87(2) 343-347
    CrossrefPubMedGoogle Scholar
  • 20 Levi M, Schouten M, van der Poll T. Sepsis, coagulation, and antithrombin: old lessons and new insights.  Semin Thromb Hemost. 2008;  34(8) 742-746
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Mann K G. Biochemistry and physiology of blood coagulation.  Thromb Haemost. 1999;  82(2) 165-174
    PubMedGoogle Scholar
  • 22 Mesters R M, Mannucci P M, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.  , [see comments] Blood. 1996;  88(3) 881-886
    PubMedGoogle Scholar
  • 23 Jochum M, Lander S, Heimburger N, Fritz H. Effect of human granulocytic elastase on isolated human antithrombin III.  Hoppe Seylers Z Physiol Chem. 1981;  362(2) 103-112
    CrossrefPubMedGoogle Scholar
  • 24 Bourin M C, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation.  Biochem J. 1993;  289(Pt 2) 313-330
    PubMedGoogle Scholar
  • 25 Kobayashi M, Shimada K, Ozawa T. Human recombinant interleukin-1 beta- and tumor necrosis factor alpha-mediated suppression of heparin-like compounds on cultured porcine aortic endothelial cells.  J Cell Physiol. 1990;  144(3) 383-390
    CrossrefPubMedGoogle Scholar
  • 26 Kessler C M, Tang Z, Jacobs H M, Szymanski L M. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity.  Blood. 1997;  89(12) 4393-4401
    PubMedGoogle Scholar
  • 27 Taylor Jr F BJ, Chang A C, Peer G T et al.. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage.  Blood. 1991;  78(2) 364-368
    PubMedGoogle Scholar
  • 28 Minnema M C, Chang A C, Jansen P M et al.. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli .  Blood. 2000;  95(4) 1117-1123
    PubMedGoogle Scholar
  • 29 Levi M. Activated protein C in sepsis: a critical review.  Curr Opin Hematol. 2008;  15(5) 481-486
    CrossrefPubMedGoogle Scholar
  • 30 Esmon C T. The roles of protein C and thrombomodulin in the regulation of blood coagulation.  J Biol Chem. 1989;  264(9) 4743-4746
    PubMedGoogle Scholar
  • 31 Bouma B N, Meijers J C. Fibrinolysis and the contact system: a role for factor XI in the down-regulation of fibrinolysis.  Thromb Haemost. 1999;  82(2) 243-250
    PubMedGoogle Scholar
  • 32 Esmon C T, Xu J, Gu J M et al.. Endothelial protein C receptor.  Thromb Haemost. 1999;  82(2) 251-258
    PubMedGoogle Scholar
  • 33 Hancock W W, Tsuchida A, Hau H, Thomson N M, Salem H H. The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy.  Transplant Proc. 1992;  24(5) 2302-2303
    PubMedGoogle Scholar
  • 34 Taylor Jr F BJ, Dahlback B, Chang A C et al.. Role of free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli .  Blood. 1995;  86(7) 2642-2652
    PubMedGoogle Scholar
  • 35 Taylor Jr F BJ, Stearns-Kurosawa D J, Kurosawa S et al.. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis.  Blood. 2000;  95(5) 1680-1686
    PubMedGoogle Scholar
  • 36 Taylor Jr F BJ, Chang A, Esmon C T, D'Angelo A, Vigano-D'Angelo S, Blick K E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.  J Clin Invest. 1987;  79(3) 918-925
    CrossrefPubMedGoogle Scholar
  • 37 Furlan M, Robles R, Galbusera M et al.. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  , [see comments] N Engl J Med. 1998;  339(22) 1578-1584
    CrossrefPubMedGoogle Scholar
  • 38 Randolph M M, White G L, Kosanke S D et al.. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli—a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli. .  Thromb Haemost. 1998;  79(5) 1048-1053
    PubMedGoogle Scholar
  • 39 de Jonge E, Dekkers P E, Creasey A A et al.. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia.  Blood. 2000;  95(4) 1124-1129
    PubMedGoogle Scholar
  • 40 Biemond B J, Friederich P W, Koschinsky M L et al.. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo.  Circulation. 1997;  96(5) 1612-1615
    CrossrefPubMedGoogle Scholar
  • 41 Schleef R R, Bevilacqua M P, Sawdey M, Gimbrone Jr M AJ, Loskutoff D J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor.  J Biol Chem. 1988;  263(12) 5797-5803
    PubMedGoogle Scholar
  • 42 Yamamoto K, Loskutoff D J. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator.  J Clin Invest. 1996;  97(11) 2440-2451
    CrossrefPubMedGoogle Scholar
  • 43 Sawdey M S, Loskutoff D J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.  J Clin Invest. 1991;  88(4) 1346-1353
    CrossrefPubMedGoogle Scholar
  • 44 ten Cate H. Pathophysiology of disseminated intravascular coagulation in sepsis.  Crit Care Med. 2000;  28(9, suppl) S9-S11
    CrossrefPubMedGoogle Scholar
  • 45 Hermans P W, Hibberd M L, Booy R et al.. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.  Lancet. 1999;  354(9178) 556-560
    CrossrefPubMedGoogle Scholar
  • 46 Westendorp R G, Hottenga J J, Slagboom P E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock.  Lancet. 1999;  354(9178) 561-563
    CrossrefPubMedGoogle Scholar
  • 47 Mesters R M, Flörke N, Ostermann H, Kienast J. Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis.  Thromb Haemost. 1996;  75(6) 902-907
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Altieri D C. Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa.  J Biol Chem. 1994;  269(5) 3139-3142
    PubMedGoogle Scholar
  • 49 Degen J L. Hemostatic factors and inflammatory disease.  Thromb Haemost. 1999;  82(2) 858-864
    PubMedGoogle Scholar
  • 50 Johnson K, Choi Y, DeGroot E, Samuels I, Creasey A, Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation.  J Immunol. 1998;  160(10) 5130-5135
    PubMedGoogle Scholar
  • 51 Kahn M L, Nakanishi-Matsui M, Shapiro M J, Ishihara H, Coughlin S R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.  J Clin Invest. 1999;  103(6) 879-887
    CrossrefPubMedGoogle Scholar
  • 52 Cunningham M A, Romas P, Hutchinson P, Holdsworth S R, Tipping P G. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages.  Blood. 1999;  94(10) 3413-3420
    PubMedGoogle Scholar
  • 53 de Jonge E, Friederich P W, Vlasuk G P et al.. Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects.  Clin Diagn Lab Immunol. 2003;  10(3) 495-497
    CrossrefPubMedGoogle Scholar
  • 54 Esmon C T. Does inflammation contribute to thrombotic events?.  Haemostasis. 2000;  30(suppl 2) 34-40
    CrossrefPubMedGoogle Scholar
  • 55 Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.  Crit Care Med. 2001;  29(7 suppl) S90-S94
    CrossrefPubMedGoogle Scholar
  • 56 Bernard G R, Vincent J L, Laterre P F Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group et al. Efficacy and safety of recombinant human activated protein C for severe sepsis.  N Engl J Med. 2001;  344(10) 699-709
    CrossrefPubMedGoogle Scholar
  • 57 Levi M, Keller T T, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system.  Cardiovasc Res. 2003;  60(1) 26-39
    CrossrefPubMedGoogle Scholar
  • 58 Baglin T. Disseminated intravascular coagulation: diagnosis and treatment.  BMJ. 1996;  312(7032) 683-687
    CrossrefPubMedGoogle Scholar
  • 59 Bhamarapravati N. Hemostatic defects in dengue hemorrhagic fever.  Rev Infect Dis. 1989;  11(suppl 4) S826-S829
    CrossrefPubMedGoogle Scholar
  • 60 Mohanty D, Ghosh K, Nandwani S K et al.. Fibrinolysis, inhibitors of blood coagulation, and monocyte derived coagulant activity in acute malaria.  Am J Hematol. 1997;  54(1) 23-29
    CrossrefPubMedGoogle Scholar
  • 61 Chuttani K, Tischler M D, Pandian N G, Lee R T, Mohanty P K. Diagnosis of cardiac tamponade after cardiac surgery: relative value of clinical, echocardiographic, and hemodynamic signs.  Am Heart J. 1994;  127(4 Pt 1) 913-918
    CrossrefPubMedGoogle Scholar
  • 62 Fera G, Semeraro N, De Mitrio V, Schiraldi O. Disseminated intravascular coagulation associated with disseminated cryptococcosis in a patient with acquired immunodeficiency syndrome.  Infection. 1993;  21(3) 171-173
    CrossrefPubMedGoogle Scholar
  • 63 Schröder S, Spyridopoulos I, König J, Jaschonek K G, Luft D, Seif F J. Thrombotic thrombocytopenic purpura (TTP) associated with a Borrelia burgdorferi infection.  Am J Hematol. 1995;  50(1) 72-73
    PubMedGoogle Scholar
  • 64 Gärdlund B. The Heparin Prophylaxis Study Group . Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases.  Lancet. 1996;  347(9012) 1357-1361
    CrossrefPubMedGoogle Scholar
  • 65 Laing R B, Brettle R P, Leen C L. Venous thrombosis in HIV infection.  , [editorial] Int J STD AIDS. 1996;  7(2) 82-85
    CrossrefPubMedGoogle Scholar
  • 66 Hayes E B, Gubler D J. Dengue and dengue hemorrhagic fever.  Pediatr Infect Dis J. 1992;  11(4) 311-317
    PubMedGoogle Scholar
  • 67 Gear J S, Cassel G A, Gear A J et al.. Outbreak of Marburg virus disease in Johannesburg.  Br Med J. 1975;  4 489-493
    CrossrefPubMedGoogle Scholar
  • 68 Limbos M A, Lieberman J M. Disseminated intravascular coagulation associated with rotavirus gastroenteritis: report of two cases.  , [see comments] Clin Infect Dis. 1996;  22(5) 834-836
    CrossrefPubMedGoogle Scholar
  • 69 McKay D G, Margaretten W. Disseminated intravascular coagulation in virus diseases.  Arch Intern Med. 1967;  120(2) 129-152
    CrossrefPubMedGoogle Scholar
  • 70 Linder M, Müller-Berghaus G, Lasch H G, Gagel C. Virus infection and blood coagulation.  Thromb Diath Haemorrh. 1970;  23(1) 1-11
    PubMedGoogle Scholar
  • 71 Clemens R, Pramoolsinsap C, Lorenz R, Pukrittayakamee S, Bock H L, White N J. Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway.  Br J Haematol. 1994;  87(1) 100-105
    CrossrefPubMedGoogle Scholar
  • 72 Badesha P S, Saklayen M G. Hemolytic uremic syndrome as a presenting form of HIV infection.  Nephron. 1996;  72(3) 472-475
    CrossrefPubMedGoogle Scholar
  • 73 Laing R W, Teh C, Toh C H. Thrombotic thrombocytopenic purpura (TTP) complicating leptospirosis: a previously undescribed association.  , [letter]. J Clin Pathol. 1990;  43(11) 961-962
    PubMedGoogle Scholar
  • 74 Ackerman A B, Chongchitnant N, Sanchez J, Guo Y. Inflammatory Diseases. Histologic Diagnosis of Inflammatory Skin Diseases. Baltimore, MD; Williams and Wilkins 1997: 170-186
    PubMedGoogle Scholar
  • 75 Golden M P, Hammer S M, Wanke C A, Albrecht M A. Cytomegalovirus vasculitis. Case reports and review of the literature.  Medicine (Baltimore). 1994;  73(5) 246-255
    PubMedGoogle Scholar
  • 76 Booss J, Dann P R, Winkler S R, Griffith B P, Kim J H. Mechanisms of injury to the central nervous system following experimental cytomegalovirus infection.  Am J Otolaryngol. 1990;  11(5) 313-317
    CrossrefPubMedGoogle Scholar
  • 77 Libman B S, Quismorio Jr F PJ, Stimmler M M. Polyarteritis nodosa-like vasculitis in human immunodeficiency virus infection.  J Rheumatol. 1995;  22(2) 351-355
    PubMedGoogle Scholar
  • 78 Calabrese L H. Vasculitis and infection with the human immunodeficiency virus.  , [review]. [53 refs] Rheum Dis Clin North Am. 1991;  17(1) 131-147
    PubMedGoogle Scholar
  • 79 Carson C W, Conn D L, Czaja A J, Wright T L, Brecher M E. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa.  J Rheumatol. 1993;  20(2) 304-309
    PubMedGoogle Scholar
  • 80 Leruez-Ville M, Laugé A, Morinet F, Guillevin L, Dény P. Polyarteritis nodosa and parvovirus B19.  Lancet. 1994;  344(8917) 263-264
    CrossrefPubMedGoogle Scholar
  • 81 Nikkari S, Mertsola J, Korvenranta H, Vainionpää R, Toivanen P. Wegener's granulomatosis and parvovirus B19 infection.  , [see comments] Arthritis Rheum. 1994;  37(11) 1707-1708
    CrossrefPubMedGoogle Scholar
  • 82 Stemerman M B, Colton C, Morell E. Perturbations of the endothelium.  Prog Hemost Thromb. 1984;  7 289-324
    PubMedGoogle Scholar
  • 83 Kaiser L, Sparks Jr H V. Endothelial cells. Not just a cellophane wrapper.  Arch Intern Med. 1987;  147(3) 569-573
    CrossrefPubMedGoogle Scholar
  • 84 Friedman H M. Infection of endothelial cells by common human viruses.  , [see comments] Rev Infect Dis. 1989;  11(suppl 4) S700-S704
    CrossrefPubMedGoogle Scholar
  • 85 Wiley C A, Schrier R D, Nelson J A, Lampert P W, Oldstone M B. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients.  Proc Natl Acad Sci U S A. 1986;  83(18) 7089-7093
    CrossrefPubMedGoogle Scholar
  • 86 Butthep P, Bunyaratvej A, Bhamarapravati N. Dengue virus and endothelial cell: a related phenomenon to thrombocytopenia and granulocytopenia in dengue hemorrhagic fever.  Southeast Asian J Trop Med Public Health. 1993;  24(suppl 1) 246-249
    PubMedGoogle Scholar
  • 87 van Dam-Mieras M C, Muller A D, van Hinsbergh V W, Mullers W J, Bomans P H, Bruggeman C A. The procoagulant response of cytomegalovirus infected endothelial cells.  Thromb Haemost. 1992;  68(3) 364-370
    PubMedGoogle Scholar
  • 88 McEver R P. GMP-140: a receptor for neutrophils and monocytes on activated platelets and endothelium.  J Cell Biochem. 1991;  45(2) 156-161
    CrossrefPubMedGoogle Scholar
  • 89 Anderson R, Wang S, Osiowy C, Issekutz A C. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes.  J Virol. 1997;  71(6) 4226-4232
    PubMedGoogle Scholar
  • 90 Sugerman R W, Church J A, Goldsmith J C, Ens G E. Acquired protein S deficiency in children infected with human immunodeficiency virus.  Pediatr Infect Dis J. 1996;  15(2) 106-111
    PubMedGoogle Scholar
  • 91 Stahl C P, Wideman C S, Spira T J, Haff E C, Hixon G J, Evatt B L. Protein S deficiency in men with long-term human immunodeficiency virus infection.  Blood. 1993;  81(7) 1801-1807
    PubMedGoogle Scholar
  • 92 Hassell K L, Kressin D C, Neumann A, Ellison R, Marlar R A. Correlation of antiphospholipid antibodies and protein S deficiency with thrombosis in HIV-infected men.  Blood Coagul Fibrinolysis. 1994;  5(4) 455-462
    PubMedGoogle Scholar
  • 93 van Gorp E C, Minnema M C, Suharti C et al.. Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever.  Br J Haematol. 2001;  113(1) 94-99
    CrossrefPubMedGoogle Scholar
  • 94 Levin J. Bleeding with infectious disease. In: Ratnoff OD, Forbes CD Disorders of Hemostasis. Orlando, FL; Grune and Stratton 1984: 367-378
    PubMedGoogle Scholar
  • 95 Nakao S, Lai C J, Young N S. Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines.  , [see comments] Blood. 1989;  74(4) 1235-1240
    PubMedGoogle Scholar
  • 96 Halstead S B. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade.  Rev Infect Dis. 1989;  11(suppl 4) S830-839
    CrossrefPubMedGoogle Scholar
  • 97 Myllylä G, Vaheri A, Vesikari T, Penttinen K. Interaction between human blood platelets, viruses and antibodies. IV. Post-rubella thrombocytopenic purpura and platelet aggregation by rubella antigen-antibody interaction.  Clin Exp Immunol. 1969;  4(3) 323-332
    PubMedGoogle Scholar
  • 98 Charkes N D. Purpuric chickenpox: report of a case, review of the literature, and classification by clinical features.  Ann Intern Med. 1961;  54 745-759
    PubMedGoogle Scholar
  • 99 Chanarin I, Walford D M. Thrombocytopenic purpura in cytomegalovirus mononucleosis.  Lancet. 1973;  2(7823) 238-239
    PubMedGoogle Scholar
  • 100 Levi M, Toh C H, Thachil J, Watson H G. British Committee for Standards in Haematology . Guidelines for the diagnosis and management of disseminated intravascular coagulation.  Br J Haematol. 2009;  145(1) 24-33
    CrossrefPubMedGoogle Scholar
  • 101 Schultz M J. Early recognition of critically ill patients.  Neth J Med. 2009;  67(9) 266-267
    PubMedGoogle Scholar
  • 102 Tromp M, Bleeker-Rovers C P, van Achterberg T et al.. Internal medicine residents' knowledge about sepsis: effects of a teaching intervention.  Neth J Med. 2009;  67(9) 312-315
    PubMedGoogle Scholar
  • 103 Warren B L, Eid A, Singer P KyberSept Trial Study Group et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.  JAMA. 2001;  286(15) 1869-1878
    CrossrefPubMedGoogle Scholar
  • 104 Kienast J, Juers M, Wiedermann C J KyberSept investigators et al. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.  J Thromb Haemost. 2006;  4(1) 90-97
    CrossrefPubMedGoogle Scholar
  • 105 Vincent J L, Angus D C, Artigas A Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.  Crit Care Med. 2003;  31(3) 834-840
    CrossrefPubMedGoogle Scholar
  • 106 Dhainaut J F, Yan S B, Joyce D E et al.. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.  J Thromb Haemost. 2004;  2(11) 1924-1933
    CrossrefPubMedGoogle Scholar
  • 107 Abraham E, Laterre P F, Garg R Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.  N Engl J Med. 2005;  353(13) 1332-1341
    CrossrefPubMedGoogle Scholar
  • 108 Dellinger R P, Levy M M, Carlet J M International Surviving Sepsis Campaign Guidelines Committee et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008.  Crit Care Med. 2008;  36(1) 296-327
    CrossrefPubMedGoogle Scholar
  • 109 Wiedermann C J, Kaneider N C. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis.  BMC Emerg Med. 2005;  5 7
    CrossrefPubMedGoogle Scholar
  • 110 Martí-Carvajal A, Salanti G, Cardona A F. Human recombinant activated protein C for severe sepsis.  Cochrane Database Syst Rev. 2007;  (3) CD004388
    PubMedGoogle Scholar
  • 111 Barie P S. “All in” for a huge pot: the PROWESS-SHOCK trial for refractory septic shock.  Surg Infect (Larchmt). 2007;  8(5) 491-494
    CrossrefPubMedGoogle Scholar

Marcel LeviM.D. 

Department Internal Medicine (F-4), Academic Medical Center, University of Amsterdam

Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands

Email: m.m.levi@amc.uva.nl

      >